Home / Medical News / Northwestern Onco-SET Launched to Provide Precision Medicine to Cancer Patients

Northwestern Onco-SET Launched to Provide Precision Medicine to Cancer Patients

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, in collaboration with Northwestern Medicine Developmental Therapeutics Institute (NMDTI) and Northwestern Memorial Hospital, has launched a new research program aimed at providing precision medicine to cancer patients.

The companies announced the launch of Northwestern Onco-SET (Sequence, Evaluate, Treat) to provide a more personalized, precision medicine option for cancer patients by combining oncology with genomics. Initially, the program will focus on patients with any type of cancer that is not responsive to traditional therapies.

According to the companies, Onco-SET personalizes cancer care for each patient by sequencing the individual genetic profile for their tumors, known as genomic profiling, and evaluating the results to provide therapies or clinical trials that will benefit them most. Some of these approaches include site-agnostic, pathway-driven treatments, which use therapies developed to target the specific genetic abnormalities of one type of cancer and applies them to treating a different form of cancer if it shares the same genetic abnormalities.

Onco-SET created the Lurie Cancer Center’s Molecular Tumor Board to evaluate and discuss the best treatment options for each patient. The board, which will review every tumor’s genomic profile, will be comprised of group of experts and cancer specialists, including pathologists, medical, surgical and radiation oncologists, as well as cancer geneticists, genome biologists, molecular scientists, bio-ethics and bioinformaticists. Treatment options made available to the Molecular Tumor Board through Onco-SET include novel therapies from a variety of early-stage clinical trials.

“Onco-SET will provide the environment and infrastructure in which we can deliver personalized cancer treatment for patients who currently have very limited options, while accelerating our other research focused on developing novel individually tailored agents,” said Francis Giles, MD, deputy director of the Lurie Cancer Center, co-chair of the Molecular Tumor Board and director of NMDTI. “We will be able to learn much more about which genomic targets are most important to effectively treat cancer and identify potential targets for which no drugs may currently exist.”

Source: Northwestern Memorial Hospital

Check Also

FDA Approves Genentech’s Rozlytrek for Patients with ROS1-Positive Metastatic NSCLC and NTRK Gene Fusion-Positive Solid Tumors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …

Leave a Reply

Your email address will not be published. Required fields are marked *